Your browser doesn't support javascript.
loading
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
Bitting, Rhonda L; Healy, Patrick; George, Daniel J; Anand, Monika; Kim, Sung; Mayer, Tina; Winters, Carol; Riggan, Colleen; Rasmussen, Julia; Wilder, Rhonda; Stein, Mark; Frizzell, Bart; Harrison, Michael R; Zhang, Tian; Lee, William R; Wu, Yuan; Koontz, Bridget F; Armstrong, Andrew J.
Afiliação
  • Bitting RL; Comprehensive Cancer Center of Wake Forest University, Departments of Internal Medicine and Radiation Oncology, Winston-Salem NC USA.
  • Healy P; Department of Biostatistics, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • George DJ; Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Pharmacology, Duke Cancer Institute Center for Prostate and Urologic Cancers,
  • Anand M; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA.
  • Kim S; Cancer Institute of New Jersey, Rutgers, NJ, USA.
  • Mayer T; Cancer Institute of New Jersey, Rutgers, NJ, USA.
  • Winters C; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA.
  • Riggan C; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA.
  • Rasmussen J; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA.
  • Wilder R; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA.
  • Stein M; Cancer Institute of New Jersey, Rutgers, NJ, USA.
  • Frizzell B; Comprehensive Cancer Center of Wake Forest University, Departments of Internal Medicine and Radiation Oncology, Winston-Salem NC USA.
  • Harrison MR; Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Pharmacology, Duke Cancer Institute Center for Prostate and Urologic Cancers,
  • Zhang T; Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Pharmacology, Duke Cancer Institute Center for Prostate and Urologic Cancers,
  • Lee WR; Department of Radiation Oncology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Wu Y; Department of Biostatistics, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Koontz BF; Department of Radiation Oncology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Armstrong AJ; Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Pharmacology, Duke Cancer Institute Center for Prostate and Urologic Cancers,
Eur Urol Oncol ; 4(6): 948-954, 2021 12.
Article em En | MEDLINE | ID: mdl-32063492
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Infarto do Miocárdio Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Oncol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Infarto do Miocárdio Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Oncol Ano de publicação: 2021 Tipo de documento: Article